These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 32926272)

  • 61. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19.
    Ni W; Yang X; Yang D; Bao J; Li R; Xiao Y; Hou C; Wang H; Liu J; Yang D; Xu Y; Cao Z; Gao Z
    Crit Care; 2020 Jul; 24(1):422. PubMed ID: 32660650
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Increasing host cellular receptor-angiotensin-converting enzyme 2 expression by coronavirus may facilitate 2019-nCoV (or SARS-CoV-2) infection.
    Zhuang MW; Cheng Y; Zhang J; Jiang XM; Wang L; Deng J; Wang PH
    J Med Virol; 2020 Nov; 92(11):2693-2701. PubMed ID: 32497323
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Inflammatory Mechanisms in COVID-19 and Atherosclerosis: Current Pharmaceutical Perspectives.
    Sagris M; Theofilis P; Antonopoulos AS; Tsioufis C; Oikonomou E; Antoniades C; Crea F; Kaski JC; Tousoulis D
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34205487
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
    Ning Q; Wu D; Wang X; Xi D; Chen T; Chen G; Wang H; Lu H; Wang M; Zhu L; Hu J; Liu T; Ma K; Han M; Luo X
    Signal Transduct Target Ther; 2022 Feb; 7(1):57. PubMed ID: 35197452
    [TBL] [Abstract][Full Text] [Related]  

  • 65. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
    Datta PK; Liu F; Fischer T; Rappaport J; Qin X
    Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
    [TBL] [Abstract][Full Text] [Related]  

  • 66. COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network.
    Kario K; Morisawa Y; Sukonthasarn A; Turana Y; Chia YC; Park S; Wang TD; Chen CH; Tay JC; Li Y; Wang JG;
    J Clin Hypertens (Greenwich); 2020 Jul; 22(7):1109-1119. PubMed ID: 32643874
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cardiovascular aspects of COVID-19.
    Kurz DJ; Eberli FR
    Swiss Med Wkly; 2020 Dec; 150():w20417. PubMed ID: 33382450
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
    Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
    J Genet; 2021; 100(1):. PubMed ID: 33707363
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
    Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
    Cadegiani FA; Goren A; Wambier CG
    Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 73. COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy.
    Xie L; Zhang Z; Wang Q; Chen Y; Lu D; Wu W
    Front Endocrinol (Lausanne); 2021; 12():772865. PubMed ID: 34867819
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cardiovascular complications in COVID-19.
    Long B; Brady WJ; Koyfman A; Gottlieb M
    Am J Emerg Med; 2020 Jul; 38(7):1504-1507. PubMed ID: 32317203
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.
    Wan Y; Shang J; Graham R; Baric RS; Li F
    J Virol; 2020 Mar; 94(7):. PubMed ID: 31996437
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The COVID-19 pandemic: a global health crisis.
    Pollard CA; Morran MP; Nestor-Kalinoski AL
    Physiol Genomics; 2020 Nov; 52(11):549-557. PubMed ID: 32991251
    [TBL] [Abstract][Full Text] [Related]  

  • 78. COVID-19, Renin-Angiotensin System and Endothelial Dysfunction.
    Amraei R; Rahimi N
    Cells; 2020 Jul; 9(7):. PubMed ID: 32660065
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cardiovascular disturbances in COVID-19: an updated review of the pathophysiology and clinical evidence of cardiovascular damage induced by SARS-CoV-2.
    Lawal IO; Kgatle MM; Mokoala K; Farate A; Sathekge MM
    BMC Cardiovasc Disord; 2022 Mar; 22(1):93. PubMed ID: 35264107
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Origin and genomic characteristics of SARS-CoV-2 and its interaction with angiotensin converting enzyme type 2 receptors, focusing on the gastrointestinal tract.
    Galanopoulos M; Doukatas A; Gazouli M
    World J Gastroenterol; 2020 Nov; 26(41):6335-6345. PubMed ID: 33244196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.